MEMORANDUM AND ORDER
Solutia Inc. (“Solutia”) brings this diversity action against FMC Corporation (“FMC”), alleging that shortcomings in FMC’s technology undermined the parties’ joint venture for production of purified phosphoric acid (“PPA”). Solutia contends that FMC knew of these deficiencies prior to the formation of the joint venture but did not disclose them. FMC moves to dismiss the Complaint pursuant to Rule 12(b)(6) of the Federal Rules of Civil Procedure. For the reasons set forth below, FMC’s motion to dismiss is granted in part and denied in part.
BACKGROUND
Solutia and FMC are publicly traded companies that produce chemicals for industrial and consumer use. (Complaint (“Compl.”) ¶ 6.) Prior to their joint venture, both companies produced PPA, which is an ingredient in many foodstuffs and also has myriad agricultural and industrial applications. (Comply 7.) While Solutia produced PPA using the traditional “thermal processed” method, FMC developed a less expensive and more efficient “wet processed” method through its Spanish subsidiary, FMC Foret. (Comphlffl 7, 21.)
In 1998, the parties discussed the formation of a joint venture that would combine each party’s phosphorous chemicals business and mass produce wet processed PPA, among other chemicals. (Compl. ¶ 8.) Solutia alleges that throughout these discussions, “FMC claimed to have the proprietary technology and know-how necessary to permit the large scale production of wet processed PPA at a substantively competitive cost.” (Compl. ¶ 9; see Compl. ¶ 22.)
On April 29, 1999, the parties entered into a Joint Venture Agreement (the “JVA”). (Comply 10.) The JVA required each party to contribute certain intellectual property and tangible assets to the joint venture. (Compl. Ex. A (“JVA”) Art. 6.) For example, Solutia was to supply its research and production facilities. (JVA § 6.2.) The JVA required FMC to grant the joint venture a license to use its wet processed technology for use at a facility to be constructed in Conda, Idaho (the “Conda Facility”). (Compl. ¶¶16; JVA § 6.4.) FMC was also obligated to deliver “all necessary technology, know-how, intellectual property, and engineering drawings so that the Joint Venture can fund and construct at ... [the Conda Facility] a new plant using the PPA technology that is capable of producing up to 80,000 metric tons of food grade wet processed [PPA]” annually. (JVA § 6.4; see Compl. ¶ 16.) FMC warranted that “it ha[d] disclosed to [Solutia] all material facts and circumstances ... which could reasonably be likely to, in [FMC]’s commercially reasonable judgment, have a material adverse effect on” the joint venture. (JVA § 16.1(v).) After the Federal Trade Commission approved the joint venture, the parties formed Astaris, LLC (“Astaris”) on April 1, 2000. (ComplV 14.) Solutia and FMC each have a fifty-percent interest in Astaris and share equally in its profits and losses. (Compl. ¶ 14; JVA §§ 5.1-5.2.)
Both parties understood that the profitability of the venture hinged on utilizing FMC’s wet processed technology to mass produce PPA. (ComplV 17.) Solutia relied on FMC’s representations concerning the viability of wet processing in deciding to contribute its $225 million phosphorous chemicals business to Astaris. (ComplV 23.) Solutia claims that after the execution of the JVA and up to April 1, 2000, FMC continued to represent that its PPA technology had been successfully uti *329 lized by FMC Foret and that the technology could be implemented at the Conda Facility on a much larger scale at a competitive cost. (Compl.™ 20-21.)
The parties executed several additional contracts to effect the JVA. Two are relevant to this action. (ComplV 18.) The first, the Asset Transfer Agreement (the “Transfer Agreement”), was entered into by FMC, Astaris and several of their subsidiaries on April 1, 2000. (Compl. Ex. C (“ATA”) at 34.) In the Transfer Agreement, FMC represented to its knowledge that the PPA technology was capable of producing “up to 80,000 metric tons of food grade wet processed [PPA]” annually. (ATA § 3.14(c); Compl. ¶ 18.) The second contract, labeled an Assignment of PPA Technology Agreement (the “Assignment Agreement”), was also executed by FMC and an Astaris subsidiary on April 1, 2000. (Compl. Ex. D (“APTA”) at 9.) In the Assignment Agreement, FMC covenanted that it would deliver to Astaris all the technology necessary to produce 80,000 metric tons of food grade PPA.' (APTA § 6.2(a).) Each agreement expressly names Solutia as a third-party beneficiary. (APTA § 8.7; ATA § 6.5; Compl. ¶ 19.)
Solutia alleges that the Conda Facility performed well below expectations and produced only less valuable grades of phosphoric acid suitable for agricultural and industrial use. (CompU 26.) According to the Complaint, FMC’s technology “failed to produce any quantity of food-grade, wet processed PPA ... resulting] in the Conda Plant’s complete inability to operate at a profitable margin.” (ComplV 25.) The phosphate ore in Idaho was not calcined and contained higher concentrations of metallic impurities than the Spanish ore at FMC Foret. (Comply 30.) Solutia attributes these differences in phosphate ore to the failure to transport the wet processed method from a small facility in Spain to a much larger one in Idaho. (Compl. ¶ 30.) Indeed, Solutia alleges that “FMC at all times knew or should have known that converting the PPA Technology from FMC Foret’s 15,000 metric ton per year operations in Huelva, Spain to the anticipated 80,000 metric ton per year operations at the Conda Plant posed serious technical problems that FMC would not be able to solve in a timely and economic way.” (Compl. ¶ 27; see Compl. ¶¶ 28-31.) The Complaint alleges that FMC never disclosed its knowledge of the problems facing the Conda Plant (Compl.™ 28-32, 35) and that, if it had, “Solutia would not have entered the JVA in April 1999” (Comply 33).
Solutia filed suit against FMC in Missouri state court on October 16, 2003. Shortly thereafter, Solutia filed for bankruptcy in the Southern District of New York. In February 2004, Solutia filed this action in the bankruptcy court and voluntarily dismissed the Missouri action. Thereafter, on FMC’s motion, this Court withdrew the reference from the bankruptcy court and assumed jurisdiction over this action.
See Solutia Inc. v. FMC Corp.,
04 Civ. 2842(WHP),
The Complaint asserts seven claims against FMC. Solutia claims that FMC’s failure to disclose the shortcomings of its PPA technology constituted breaches of section 16.1 of the JVA, section 3.14(c) of the Transfer Agreement and FMC’s fiduciary duty, as well as negligent misrepresentation and fraud in the inducement. (Compl.™ 43-55, 62-87.) Solutia also claims that FMC failed to deliver technology capable of producing 80,000 metric tons of food grade PPA to Astaris, in breach of section 6.4 of the JVA and section 6.2(a) of the Assignment Agreement. (Compm 38-41, 57-60.)
Solutia seeks at least $322 million in compensatory damages, lost profits and *330 punitive damages. (Compl.lffl 41, 48, 55, 60.) In the alternative, Solutia seeks rescission of the JVA and restitution for the value of the assets Solutia transferred to Astaris. (Compl.lffl 69, 77, 87.)
FMC moves to dismiss the Complaint on the grounds that (1) Solutia lacks standing to sue on its own behalf because the Complaint alleges injury borne directly by the joint venture; (2) Solutia’s claims are premature until an accounting of Astaris occurs; (3) the fraud and negligent misrepresentation claims are precluded by the JVA’s merger clause; (3) the fraud and negligent misrepresentation claims are barred to the extent they duplicate Solu-tia’s breach of contract claims; and (5) the claims for breach of the Asset Transfer Agreement are time-barred.
DISCUSSION
New York law governs Solutia’s contract claims. (JVA ¶22; APTA ¶8.2; ATA ¶ 6.4.) As to the tort claims, FMC contends that the contractual choice-of-law provisions “demonstrate that the parties intended all possible claims between them related to the joint venture to be dealt with under the JVA, and thus governed by New York law.” (Defendant’s Memorandum in Support of Motion to Dismiss (“Def.Mem.”) at 13.) Solutia resists taking a position concerning whether New York or Missouri supplies the governing law for its tort claims, but represents that there is no “distinction between New York law and Missouri law on those counts.” (Transcript of Oral Argument, Oct. 14, 2004 (“Tr.”) at 22.) Accordingly, this Court applies New York law to all claims.
I. Standard on a Motion to Dismiss
On a motion to dismiss under Rule 12(b)(6), a court must accept the material facts alleged in the complaint as true and construe all reasonable inferences in a plaintiffs favor.
Grandon v. Morrill Lynch & Co.,
While the court’s focus is primarily on the complaint, the court may also consider “any written instrument attached to [the complaint] as an exhibit or any statements or documents incorporated in it by reference.”
Rothman v. Gregor,
II. Standing
FMC argues that Solutia lacks standing because Astaris suffered the direct injury. FMC contends that Solutia’s injury is derivative in that it is the decreased value of its investment. Thus, the impact on Solu-tia is limited to its position as an Astaris shareholder. According to FMC, Solutia has standing to bring a derivative suit on behalf of Astaris but lacks standing to sue individually.
While the parties characterize their relationship as a joint venture, they formed a new corporation to conduct their purified phosphoric acid business. Once Astaris *331 came into being, Solutia and FMC were not only joint venturers under the JVA but shareholders in a Delaware limited liability company.
Under New York law, “[a]n individual shareholder has no right to bring an action in his own name and in his own behalf for a wrong committed against the corporation, even though the particular wrong may have resulted in a deprecation or destruction of the value of his corporate stock.”
Fifty States Mgmt. Corp. v. Niagara Permanent Sav. & Loan Assoc.,
However, “where the plaintiffs injury is direct, the fact that [the corporation] may also have been injured and could assert its own claims does not preclude the plaintiff from asserting its claim directly.”
Excimer
Assocs.,
Inc. v. Vision, Inc.,
FMC contends that, to have individual standing, a shareholder’s injury must be different from the injury any other shareholder would suffer, and must be more than merely a decrease in the value of its investment. (Def. Mem. at 15-19.) None of the cases relied on by FMC, however, impose such an individualized injury requirement on a shareholder to whom the defendant violated a duty independent of the corporation. In
Paulson v. Margolis,
the First Department held that one shareholder could not sue another because the harm was to the corporation only
and
the plaintiff had not adequately alleged that the defendant owed him a separate duty.
Moreover, New York courts consistently hold that where an independent duty exists, a shareholder may sue on his own behalf even for the loss of value in his investment.
See Gen. Rubber, 215
N.Y. at 22-23,
A. Tort Claims
FMC argues that Solutia lacks standing to assert any of its claims because “FMC could not have injured Solutia without first injuring Astaris.” (Def. Mem. at 15.) However, FMC’s contention is premised on a generalization that misconstrues the nature of many of Solutia’s claims, including those in tort.
FMC contends that “each count [of the Complaint] addresses a common core of allegations: by delivering to Astaris allegedly deficient PPA Technology, FMC damaged Astaris, and thus devalued Solutia’s investment therein.” (Def. Mem. at 15.) In fact, Solutia’s breach of fiduciary duty, fraud and negligent misrepresentation claims allege that prior to the April 2000 incorporation of Astaris, FMC failed to disclose material facts concerning the capability of its PPA technology. (Compilé 61-87.) The adequacy of the technology actually delivered to Astaris is relevant only to the extent it reflects FMC’s knowledge prior to April 1, 2000.
To the extent that FMC’s alleged failure to disclose injured Solutia, it was as a potential investor in the joint venture, not as a shareholder.
Cf. Paulson,
In this realm, courts have consistently held that a shareholder such as Solutia has standing to sue on its own behalf where it claims “that it was fraudulently induced to become a shareholder in the first place.”
Lakonia, Mgmt. Ltd. v. Meriwether,
Moreover, prior to the shareholder relationship in Astaris, FMC owed an independent duty arising from its joint venture relationship that also confers standing on Solutia.
See Abrams,
N.Y.2d at 953;
Benedict,
FMC argues that any rights springing from a duty existing before formation of Astaris are not actionable to the extent they interfere with the rights of Astaris or its creditors. However, the Complaint alleges that FMC’s failure to disclose material information caused Solutia to enter the joint venture — an injury relevant only to Solutia and pre-dating the corporation. These duties are “independent of and extrinsic to the corporate entity,”
Fifty States Mgmt.,
*334 Because Solutia’s tort claims allege a harm to Solutia distinct from any harm to Astaris and implicate an independent duty owed by FMC, Solutia has standing to assert those claims on its own behalf and need not proceed derivatively.
B. Breach of the JVA
Solutia claims that FMC breached two separate provisions of the JVA. First, the Complaint alleges a breach of section 6.4 in that FMC “failed to deliver the technology, know-how, intellectual property and engineering drawings necessary for the Joint Venture to construct a new plant at Conda, Idaho that is capable of producing any food-grade wet processed [PPA].” (CompLfl 39.) Second, the Complaint alleges that FMC breached the section 16.1 warranty by failing to disclose to Solutia “that significant technical problems existed that could prevent the successful implementation and/or adaptation of its PPA Technology to the Conda Plant operations.” (Compl.lHI 44r-45.)
1. Section 6.1 of the JVA
FMC contends that Solutia lacks standing to sue FMC for failing to deliver the PPA technology promised in the JVA because such a breach, if true, harmed Astaris directly and Solutia only as a shareholder thereof.
Solutia alleges that FMC’s failure to deliver the promised PPA technology required Solutia “to infuse a substantial amount of additional capital.” (Comply 36.) This additional contribution, however, was contractually required. (Tr. at 30.) As such, Solutia’s additional expenditures do not constitute a direct injury sufficient to give Solutia standing.
See Abrams,
While the JVA created independent contractual obligations running from FMC to Solutia, many of those duties folded into FMC’s later undertakings to Astaris on its incorporation. New York courts have held that a pre-incorporation contractual obligation between joint venturers survives incorporation of the joint venture only to the extent that the obligation does not “conflict with the corporation’s functioning” and the rights of third-party creditors are not involved.
Richbell Info. Servs., Inc. v. Jupiter Partners, L.P.,
Accordingly, Solutia lacks standing to sue FMC on its own behalf for breach of section 6.4 of the JVA.
2. Section 16.1 of the JVA
Through section 16.1 of the JVA, FMC warranted that, as of April 29, 1999, it had disclosed to Solutia all material facts concerning its PPA technology. (JVA § 16.1.) As discussed in connection with Solutia’s tort claims, FMC’s alleged failure to fully disclose to Solutia the capabilities of its PPA technology harmed Solutia directly. To this end, Solutia claims that upon entering the joint venture it divested itself of its entire phosphorous chemicals business. (ComplJ 36.) This divestiture occurred prior to the incorporation of As-taris, and thus was an injury that befell Solutia before it became an Astaris shareholder. Astaris itself was harmed only indirectly.
Cf. Wolf,
Moreover, unlike section 6.4, section 16.1 of the JVA created a duty that survived the incorporation of the joint venture and was at all times extrinsic to the corporate entity.
See Wolfson,
As such, FMC’s duty to Solutia remains independent of Astaris, and Solutia has standing to enforce it.
See Higgins,
C. Breach of the Assignment and Transfer Agreements
Through the Transfer Agreement, FMC covenanted to Astaris that it had technology capable of producing 80,000 metric tons of PPA annually. (ATA § 3.14(c).) In the Assignment Agreement, FMC represented *336 to Astaris that it would deliver that technology to the corporation. (APTA § 6.2.) FMC contends that Solutia lacks standing to sue FMC for breaches of the Assignment and Transfer Agreements because the alleged injuries lie with Astaris—not Solutia, and Solutia was not a party to those contracts. (Def. Mem. at 23-24.)
A breach of contract by FMC harms Astaris first and foremost because Astaris is the contracting party.
See Goldstein,
Solutia maintains that it can properly sue for FMC’s alleged breaches of the Assignment and Transfer Agreements because those contracts expressly identify Solutia as a third-party beneficiary. (Plaintiffs Memorandum in Opposition to Motion to Dismiss (“Pl.Mem.”) at 13-16;
see
APTA § 8.7; ATA § 6.5.) Indeed, the promisor in a contract owes a third-party beneficiary a duty independent of its duty to the promisee, even if there is no separate performance to the third-party beneficiary.
See Genen v. Metro-North Commuter R.R.,
Under New York law, an intended third-party beneficiary has standing to enforce an agreement entered into between others.
See State of Calif. Pub. Employees’ Ret. Sys. (“CalPERS”) v. Shearman & Sterling,
“A third party seeking to recover on a contract must establish that a binding contract exists between other parties; that this contract was intended for his benefit; and that the benefit to him was direct rather than incidental.”
Internationale Nederlanden (U.S.) Capital Corp. v. Bankers Trust Co.,
Here, the Assignment and Transfer Agreements leave no doubt that the contracting parties (ie., FMC, Astaris and their subsidiaries) intended to invest Solu-tia with certain third-party rights and remedies. The Assignment Agreement explicitly states:
Except with respect to Solutia Inc., which is a third party beneficiary of this Assignment Agreement, nothing herein expressed or implied is intended or shall be construed to confer upon or give any person or entity other than the parties hereto and their respective successors, legal representatives and permitted assigns any rights or remedies under or by reason of this Agreement.
(APTA § 8.7 (emphasis added).) The Transfer Agreement contains a similar provision: “[N]othing contained herein shall be construed or deemed to confer any benefit or right upon any third party;
provided, however,
that Solutia shall be a third party beneficiary of this Agreement.” (ATA § 6.5.) The clear implication of these provisions is that the contracting parties intended to confer rights and remedies on Solutia under the Assignment and Transfer Agreements.
See Fourth Ocean Putnam,
However, mere intent to confer third-party rights is insufficient; there must be a benefit that is explicit and direct. Bu
rns Jackson,
The Assignment and Transfer Agreements did not provide for any performance to be made directly to Solutia.
Cf. Internationale Nederlanden,
Accordingly, Solutia lacks standing to sue individually on its own behalf for FMC’s alleged breaches of the Assignment and Transfer Agreements. 2
III. Need for an Accounting
FMC contends that all of Solutia’s claims are premature because an accounting of Astaris has not yet been performed. Without an accounting, FMC contends, this Court cannot determine the extent to which FMC’s alleged actions affected As-taris’ value, Solutia’s investment or third- *339 party creditors, and whether either party has obligations to the other arising from the joint venture. (Def. Mem. at 24-28.) FMC notes that Astaris has many operations in addition to PPA processing, so that Solutia’s investment in the joint venture would not have been “destroyed” by a failure of the PPA technology FMC had contributed.
New York’s law governing partnerships is generally extended to joint ventures,
See Ebker v. Tan Jay Int’l Ltd.,
The claims that Solutia has standing to bring do not depend on a prior accounting. These claims assert that Solu-tia would not have entered the joint venture had Astaris fully disclosed the problems with its PPA technology. Rather than the profits Astaris may have lost, Solutia seeks the return of its contributions to the joint venture and consequential damages from the lost opportunity— amounts quantifiable without an accounting of Astaris. This is true even with respect to the alleged breach of the JVA warranty, section 16.1, because that breach would have occurred as soon as FMC signed the contract knowing that it had not disclosed all material facts to Solutia. “[W]here a joint venture agreement is breached before any business is done thereunder ..., there is no need to resort to an equitable accounting, and an action at law for damages will lie.” 16 N.Y. Jur.2d Bus. Relationships § 1962;
see B.D. & F. Realty Corp. v. Lerner,
Accordingly, Solutia’s surviving claims are not barred for want of a prior accounting.
IV. Effect of the JVA’s Merger Clause
FMC contends that the JVA’s merger clause precludes Solutia’s claims of fraud and negligent misrepresentation. Section 23.4(a) states that the JVA “constitutes the entire agreement between the parties pertaining to the subject matter hereof, and all prior representations, discussions and negotiations between the parties ... pertaining to the subject matter of this Agreement are superseded.” (JVA § 23.4(a).) That section incorporates by reference a letter agreement previously entered into by the parties. (JVA § 23.4(a).) The letter agreement provides: “Except for the matters expressly specified in th[e] letter or in any such formal written definitive contract, neither party *340 shall be entitled to rely on any statement, promise, agreement or understanding, whether oral or written ... in connection with the Possible Transaction.” (Def. Mem. Ex. A: Letter Agreement, dated Nov. 18, 1998 ¶ 4.)
New York courts hold a contract fully integrated by a merger clause subject to the parole evidence rule, prohibiting the introduction of extrinsic evidence.
Mfrs. Hanover Trust Co. v. Yanakas,
Solutia contends that the JVA only contains a general merger clause, and therefore does not bar its claims of fraud. (PI. Mem. at 33-35.) FMC, in contrast, argues that the Letter Agreement is sufficiently specific to preclude Solutia’s claims. (Tr. at 17.)
However, where the alleged misrepresentations supporting a claim of fraud arise from facts within the “peculiar knowledge” of a party, even a specific disclaimer as to reliance on those representations does not bar a fraud claim.
Warner Theatre Assocs. Ltd. P’ship v. Metro. Life Ins. Co.,
Solutia has adequately pled reliance on representations that concern facts within the peculiar knowledge of FMC. For example, FMC’s allegedly fraudulent misrepresentations concern the use of the PPA technology at FMC Foret, FMC’s tests of the PPA technology on various ores and an internal FMC report regarding the efficacy of using the PPA technology at the Conda Facility. (Compl.¶¶ 20-22, 29-31.) Unlike the cases on which FMC relies, all of the alleged misrepresentations in this action concern the capability of proprietary technology, which is necessarily in the peculiar knowledge of its owner.
Cf. DynCorp v. GTE Corp.,
FMC contends that the peculiar knowledge exception does not apply to a negligent misrepresentation claim. (Tr. at 15.) On the contrary, the same reasoning has equal force when applied to Solutia’s claim of negligent misrepresentation. Regardless of the cause of action, the information FMC withheld or misrepresented was within its peculiar knowledge, and Solutia can claim reasonable reliance on FMC’s
*341
representations to support either a fraud or negligent misrepresentation claim.
See Dimon,
Moreover, the parties were linked in a joint venture which, as discussed
supra,
infused fiduciary duties in their relationship.
See, e.g., Meinhard,
Accordingly, Solutia’s claims of fraud and negligent misrepresentation based on representations extraneous to the contract are not precluded by the JVA’s merger clause.
V. Duplication of Tort and Contract Claims
Lastly, FMC challenges Solutia’s fraud and negligent misrepresentation claims on the ground that they are premised on the same allegations that underlie Solutia’s breach of contract claims.
As discussed above, this Court holds that Solutia lacks standing to assert each of its breach of contract claims with the exception of its claim that FMC breached section 16.1 of the JVA by failing to disclose material information concerning its PPA technology. By its terms, section 16.1 encompasses only representations and omissions occurring prior to the date of the JVA, April 29, 1999. (JVA § 16.1.) Solutia’s fraud and negligent misrepresentation claims, by contrast, implicate a much broader period, culminating on As-taris’ April 1, 2000 incorporation. (Compl.1H171, 78.) Because no breach of contract claim can be stated for events occurring between April 29, 1999 and April 1, 2000, Solutia’s claims for fraud and negligent misrepresentation are cognizable to the extent they depend on representations and omissions during that time period.
See Richbell,
Generally, under New York law, “[a] separate cause of action seeking damages in fraud cannot stand when the only fraud alleged relates to a breach of contract.”
Gizzi v. Hall,
The gravamen of Solutia’s fraud and negligent misrepresentation claims is that FMC misrepresented that it
had
technology that could be used to produce 80,-000 metric tons of wet processed, food grade PPA each year and that its
current
use demonstrated the effectiveness its technology. (Compl.¶¶ 20-22, 71-72, 78-79.) As FMC discerns, the alleged misrepresentations may be accurately characterized as concerning “whether the PPA Technology in use in Spain could be successfully adapted to Conda
in the future.
” (Defendant’s Reply Memorandum in Support of Motion to Dismiss at 7.) However, even viewed in such a light, the Complaint alleges that Solutia was fraudulently induced to enter the JVA because FMC had misrepresented its then-present technological capability and concealed material information. (Compl.¶ 32, 75, 83.)
See Great Earth,
CONCLUSION
For the reasons set forth above, FMC’s motion to dismiss is granted in part and denied in part. Specifically, this Court dismisses Solutia’s claims for breach of section 6.4 of the Joint Venture Agreement (Count I) and for breach of the Assignment and Transfer Agreements (Counts III and TV) with prejudice. FMC’s motion to dismiss Solutia’s claims for breach of section 16.1 of the Joint Venture Agreement (Count II), breach of fiduciary duty (Count V), negligent misrepresentation (Count VI) and fraud and fraud in the inducement (Count VII) is denied.
Notes
. New York corporate law applies in full force to limited liability companies such as Astaris.
Weber v. King,
. Because this Court holds that Solutia lacks standing to sue for breach of the Transfer Agreement, it need not consider FMC's argument that those claims are time-barred under the agreement's two-year statute of limitations. (Def. Mem. at 34-35.)
